VBIV logoVBIV
VBI Vaccines Inc.

25,013
Loading...
Loading...
News
all
press releases
CarMax Well Positioned For Growth, Says Wedbush: Retail Sentiment Improves
Wedbush said while tariffs could raise parts costs, the overall impact on reconditioning expenses is limited, and CarMax is largely shielded from supply disruptions as it sources most inventory independently.
Stocktwits·5mo ago
News Placeholder
More News
News Placeholder
CarMax Shares Dive On Weak Q4 Print, But Retail Bets Trump Tariffs Will Rev Up Used Car Demand
Stock fell 17%, its worst single-day decline since September 2022.
Stocktwits·6mo ago
News Placeholder
Helen Of Troy Stock Inches Up After Q2 Earnings Beat Estimates, Retail Sentiment Remains Lukewarm
The maker of household and beauty products such as Vicks, Braun, and Revlon also reaffirmed its full-year outlook for net sales, adjusted EPS, and adjusted EBITDA
Stocktwits·1y ago
News Placeholder
VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior...
Business Wire·1y ago
News Placeholder
Pre-Market Movers: Retail's Pulse On Faraday Future, Nvidia and VBI Vaccines
EV-maker Faraday Future had some pleasing news for investors, as shares rocketed before the bell. Nvidia, meanwhile, rode on the cheer surrounding a rival’s strong earnings. But for VBI Vaccines, it has come down to a fight for survival.
Stocktwits·1y ago
News Placeholder
VBI Vaccines Announces Results of Annual General Meeting
VBI Vaccines Inc. (Nasdaq: VBIV) ('VBI' or the 'Company'), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting...
Business Wire·1y ago
News Placeholder
VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced new interim tumor response...
Business Wire·1y ago
News Placeholder
VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new interim tumor...
Business Wire·1y ago
News Placeholder
VBI Vaccines Reports First Quarter 2024 Financial Results
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced...
Business Wire·1y ago
News Placeholder
VBI Vaccines Reports Full Year 2023 Financial Results
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided a business update and announced...
Business Wire·1y ago

Latest VBIV News

View

Advertisement|Remove ads.

Advertisement|Remove ads.